U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma « New Drug Approvals

U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma « New Drug Approvals:

'via Blog this'

Mast Ischemia Drug Gets Orphan Drug Designation « New Drug Approvals

Mast Ischemia Drug Gets Orphan Drug Designation « New Drug Approvals:

'via Blog this'

Chugai Pharma to commercialize Helsinn’s Anamorelin for anorexia-cachexia syndrome in Germany, France, Benelux, UK and Ireland « New Drug Approvals

Chugai Pharma to commercialize Helsinn’s Anamorelin for anorexia-cachexia syndrome in Germany, France, Benelux, UK and Ireland « New Drug Approvals:

'via Blog this'

QbD: new Guidance from EMA and FDA « New Drug Approvals

QbD: new Guidance from EMA and FDA « New Drug Approvals:

'via Blog this'

Medicine Can be Sweet, Glycosylated analogues of pramlintide were synthesized » All About Drugs

Medicine Can be Sweet, Glycosylated analogues of pramlintide were synthesized » All About Drugs:

'via Blog this'

Zalicus starts Phase Ib clinical trial of neuropathic pain drug » All About Drugs

Zalicus starts Phase Ib clinical trial of neuropathic pain drug » All About Drugs:

'via Blog this'

All About Drugs

All About Drugs:

'via Blog this'